These mid-cap stocks were the best performers in the last week. Are they in your portfolio?

MicroStrategy's share surge reflects the growing conviction that US 'small-cap' stocks are set for stardom under the Trump ...

Hims & Hers Health (HIMS) stock could soon stage a rebound, creating an intriguing opportunity for options bulls ...

Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The ...

BofA Securities has recently reduced Hims & Hers Health Inc (HIMS) stock to Underperform rating, as announced on November 14, 2024, according to Finviz. Earlier, on August 22, 2024, Needham had ...

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly’s ...

Citi notes that the FDA said in a status report filed in a Texas court that it needs more time to determine if Eli Lilly’s (LLY) tirzepatide ...

Schrödinger is an unusual animal in the AI in drug discovery landscape. In a new interview with CEO Ramy Farid, STAT’s ...

Him & Hers Health (NYSE:HIMS) closed up ~10% Thursday after a federal court in Texas administratively closed a case in which a compounding drugs industry association challenged the U.S. FDA's ...

The Illinois Supreme Court on Thursday overturned actor Jussie Smollett’s conviction on charges that he staged a racist and ...

In a report released today, Daniel Grosslight from Citi maintained a Hold rating on Hims & Hers Health (HIMS – Research Report), with a price target of $24.00. Don't Miss our Black Friday Offers: ...

While the biggest driver of growth for Amazon (NASDAQ: AMZN) has been coming from its cloud computing division, Amazon Web ...